AstraZeneca and Incyte to assess new lung cancer regimen

AstraZeneca and its biologics division MedImmune are expanding their partnership with Incyte to assess a potential new treatment regimen for lung cancer.

The companies will partner to evaluate the efficacy and safety of Incyte's investigational selective IDO1 enzyme inhibitor epacadostat in combination with AstraZeneca's Imfinzi, a human monoclonal antibody directed against PD-L1.

A phase III trial will be conducted in patients with locally-advanced unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy.

This study will be co-funded by all of the companies involved and will be conducted by AstraZeneca, with patient enrolment set to commence in the first half of 2018.

Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "We are pleased to build on recent data from the PACIFIC trial to further explore how Imfinzi, in combination with an IDO inhibitor, could provide additional benefit to patients with locally-advanced lung cancer."

This agreement builds on an existing clinical collaboration for Imfinzi and epacadostat that was first launched by the companies in May 2014.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.